Cancer & Oncology

Plain-English briefings on oncology research — trials, targeted therapies, immunotherapy, and screening — every claim linked to its primary source.

2026-07-18 · 2 sources How pembrolizumab reset the bar for advanced melanoma: what KEYNOTE-006 showed

KEYNOTE-006, a randomized phase 3 trial, found the anti-PD-1 antibody pembrolizumab improved progression-free and overall survival versus ipilimumab in advanced melanoma, with fewer severe side effects.